Rubedo Life Sciences

Rubedo Life Sciences company information, Employees & Contact Information

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.
Looking for a particular Rubedo Life Sciences employee's phone or email?

Rubedo Life Sciences Questions

News

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board - Yahoo Finance

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board Yahoo Finance

Rubedo Life Sciences Appoints Former Allergan Executive and Biotechnology Veteran Dr. Frederick Beddingfield III as CEO - Business Wire

Rubedo Life Sciences Appoints Former Allergan Executive and Biotechnology Veteran Dr. Frederick Beddingfield III as CEO Business Wire

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial - Business Wire

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial Business Wire

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial - BioSpace

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial BioSpace

Backed by Khosla Ventures, Rubedo Life Sciences Secures $12M for Drug Discovery Platform - HIT Consultant

Backed by Khosla Ventures, Rubedo Life Sciences Secures $12M for Drug Discovery Platform HIT Consultant

Rubedo announces first-in-class drug candidate for dermatology - Longevity.Technology

Rubedo announces first-in-class drug candidate for dermatology Longevity.Technology

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital - Business Wire

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital Business Wire

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023 - Business Wire

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023 Business Wire

Top Rubedo Life Sciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant